The most common side effect of Spiriva is dry mouth, affecting roughly 3% of people with COPD who take it. Other frequently reported effects include sore throat, cough, sinusitis, and headache. Most of these are mild and tend to ease as your body adjusts to the medication over the first few weeks.
Dry Mouth: The Most Frequent Side Effect
Spiriva works by blocking a chemical messenger called acetylcholine in the airways, which relaxes the muscles around your breathing passages and keeps them open. But that same blocking action also reduces saliva production, which is why dry mouth is the hallmark side effect. In clinical trials, about 2.9% of COPD patients experienced it. For people using Spiriva for asthma, the rate was lower, around 1.2%. The dryness is usually described as mild.
If it bothers you, sipping water frequently, chewing sugar-free gum, or using a saliva substitute can help. One thing worth knowing: persistent dry mouth over the long term has been linked to an increased risk of dental cavities, so staying on top of dental hygiene matters if you use Spiriva for months or years.
Other Common Side Effects
Beyond dry mouth, the side effects that show up most often in clinical trials include:
- Sore or dry throat: A scratchy feeling after inhaling the powder, which often improves with a sip of water after each dose.
- Cough: The inhaled powder itself can irritate the airways briefly, triggering a cough right after use.
- Sinusitis and upper respiratory infections: These were among the most commonly reported events in pooled trial data, though they also occurred frequently in people taking a placebo.
- Headache and bronchitis: Both appeared at rates above 2% in asthma trials.
These effects generally don’t require you to stop the medication. Many of them fade during the first weeks of treatment as your body adjusts.
Urinary Retention
Because Spiriva’s active ingredient affects the same chemical signaling system that controls bladder muscle contraction, it can make it harder to fully empty your bladder. In pooled clinical trial data, the relative risk of urinary retention was roughly 11 times higher with Spiriva compared to placebo. In absolute numbers this is still uncommon, but it’s a meaningful concern if you already have an enlarged prostate or a bladder outlet obstruction.
Signs to watch for include difficulty starting urination, a weak stream, a feeling that your bladder isn’t empty after using the bathroom, or painful urination. If these develop, it’s worth getting evaluated promptly, because untreated urinary retention can become a medical emergency.
Eye Pressure and Glaucoma Risk
Spiriva can raise pressure inside the eye, which is a problem specifically for people with narrow-angle glaucoma or those at risk for it. This is most likely to happen if the inhaled medication accidentally contacts the eyes, something that can occur if the mouthpiece isn’t sealed properly or if you use the mist inhaler version without care.
Symptoms of a sudden spike in eye pressure include eye pain or discomfort, blurred vision, and seeing halos or colored rings around lights, often with redness. This combination needs immediate medical attention because it can permanently damage vision if the pressure isn’t relieved quickly.
HandiHaler vs. Respimat: Are the Risks Different?
Spiriva comes in two forms: the HandiHaler (a dry powder capsule you puncture and inhale) and the Respimat (a slow-mist inhaler). The everyday side effects like dry mouth and sore throat are similar between the two, but their safety profiles diverged in one important area.
A large observational study published in the European Respiratory Journal found that Respimat was associated with roughly a 30% higher risk of death compared to the HandiHaler, driven primarily by cardiovascular and cerebrovascular causes. The risk was concentrated in people who already had underlying heart disease, where the increased risk reached 36%. The leading theory is that Respimat delivers the drug more efficiently, producing higher blood levels that amplify effects on heart rhythm. Following these findings, the Respimat dose was reduced from 5 micrograms to 2.5 micrograms for COPD, which appears to have narrowed this safety gap.
Cardiovascular Safety Overall
Concerns about Spiriva and heart risk have been studied extensively. A large pooled analysis of 30 trials covering nearly 20,000 patients actually found a lower rate of major cardiovascular events in the Spiriva group compared to placebo. The rate was 2.15 events per 100 patient-years with Spiriva versus 2.67 with placebo, a relative risk reduction of about 17%. Heart failure risk was also modestly lower. Stroke risk was essentially the same between the two groups.
So for most people, Spiriva does not appear to increase heart risk and may even have a slight protective effect. The exception, as noted above, was the older high-dose Respimat formulation in people with existing cardiovascular disease.
Allergic Reactions
Serious allergic reactions to Spiriva are rare but have been reported both in clinical trials and after the drug reached the market. Symptoms can include hives, rash, itching, and swelling of the face, lips, tongue, or throat. In the most severe cases, this swelling can make it difficult to breathe or swallow. Paradoxical bronchospasm, where the airways tighten instead of opening, has also been reported.
These reactions typically happen shortly after a dose. If you notice facial swelling, throat tightness, or sudden worsening of your breathing right after using the inhaler, stop using it and seek emergency care.
Side Effects in Children
Spiriva Respimat is approved for asthma maintenance in children aged 6 and older. The FDA reviewed all pediatric adverse event reports through early 2018 and found only two serious cases, neither of which revealed a new safety signal. The most common side effects in younger patients mirror those in adults: sore throat, headache, bronchitis, and sinusitis. No fatal pediatric cases were identified in the postmarketing review.